While limited studies on CB2-receptor agonist-mediated inflammation have been reported, this study shows that the CB2 inverse agonist SMM-189 also suppresses experimental colitis, most likely through inhibition of Th17 cells and neutrophils, and induction of MDSCs, NKT cells, and anti-inflammatory PKA signaling pathways. This evidence concerns the gene CNR2 and colitis.